Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-s...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

AnonMav Jan. 7 at 5:02 AM

The sharpest rallies often come after the sharpest drops because the selling pressure is exhausted. $NEO is living proof of that. Resistance: $13-$14 zone Support: $5.60 The flow: someone bought Feb 20 2026 $9 ITM calls. https://share.trendspider.com/chart/NEO/949933jgv4i?_go=anonmav

0 · Reply

StockConsultant Jan. 6 at 4:13 PM

$NEO Neogenomics stock with a top of range breakout

0 · Reply

AnyMonkey Dec. 26 at 6:09 PM

$NEO lets keep the long steady climb going!

0 · Reply

Glizzy_Gladiator Dec. 24 at 5:49 PM

$NEO Take your time big guy we know what direction you’re going in the long run

0 · Reply

kiwitc2000 Dec. 24 at 4:15 PM

$NEO Curling up nicely above support with volume low on red days and above average on green. Overall the volume is low, so all it would take is a couple of big trades to start rolling. Watching carefully.

1 · Reply

ValueVester Dec. 16 at 3:01 AM

$NEO $NEO With Natera withdrawing their appeal regarding the RaDaR patent, suitors will now look more favorable on Neogenomics when it comes to an acquisition. I wouldn’t be surprised if NEO is now much more easily shopped around. Buyout would be $18 - $24.

0 · Reply

DriveForShow Dec. 15 at 5:53 PM

$NEO Good news. Natera has withdrawn their appeal regarding RaDaR patent.

1 · Reply

GeeRam23 Dec. 15 at 12:23 PM

$NEO

0 · Reply

MaximillionJewell Dec. 14 at 7:11 PM

$NEO 🧐

1 · Reply

Estimize Dec. 11 at 12:00 PM

Wall St is expecting 0.04 EPS for $NEO Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/neo?chart=historical&metric_name=eps&utm_cont

0 · Reply

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 7:05 AM EST - 9 days ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

Dec 15, 2025, 7:05 AM EST - 24 days ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 10, 2025, 7:05 AM EST - 4 weeks ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 8, 2025, 8:05 AM EST - 4 weeks ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Nov 14, 2025, 12:41 PM EST - 7 weeks ago

Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:05 AM EST - 2 months ago

NeoGenomics to Participate in Upcoming Investor Conferences

Oct 30, 2025, 12:51 PM EDT - 2 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 28, 2025, 3:11 PM EDT - 2 months ago

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:05 AM EDT - 2 months ago

NeoGenomics Reports Third Quarter 2025 Results

Oct 14, 2025, 7:05 AM EDT - 3 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 7, 2025, 7:05 AM EDT - 3 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Sep 17, 2025, 7:58 AM EDT - 4 months ago

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

Aug 29, 2025, 1:04 PM EDT - 4 months ago

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Aug 29, 2025, 7:05 AM EDT - 4 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Aug 12, 2025, 6:56 PM EDT - 5 months ago

Neo Performance Materials Inc. (NOPMF) Q2 2025 Earnings Conference Call Transcript

Jul 30, 2025, 7:05 AM EDT - 5 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 4:54 PM EDT - 5 months ago

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:05 AM EDT - 5 months ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 6 months ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 6 months ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

May 28, 2025, 7:10 AM EDT - 8 months ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 8 months ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 30, 2025, 9:00 AM EDT - 9 months ago

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

Apr 29, 2025, 12:18 PM EDT - 9 months ago

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 8:00 AM EDT - 9 months ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 9 months ago

NeoGenomics Reports First Quarter 2025 Results

Apr 22, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 7, 2025, 7:05 AM EDT - 9 months ago

NeoGenomics Completes Acquisition of Pathline

Apr 1, 2025, 7:05 AM EDT - 10 months ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Mar 10, 2025, 7:00 AM EDT - 10 months ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Feb 28, 2025, 3:39 AM EST - 11 months ago

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 18, 2025, 12:22 PM EST - 11 months ago

NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 7:05 AM EST - 11 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Jan 29, 2025, 8:05 AM EST - 1 year ago

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

Jan 15, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Jan 10, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Announces Chief Executive Officer Succession

Jan 6, 2025, 7:55 AM EST - 1 year ago

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:05 AM EST - 1 year ago

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

Dec 9, 2024, 8:10 AM EST - 1 year ago

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

AnonMav Jan. 7 at 5:02 AM

0 · Reply

StockConsultant Jan. 6 at 4:13 PM

$NEO Neogenomics stock with a top of range breakout

0 · Reply

AnyMonkey Dec. 26 at 6:09 PM

$NEO lets keep the long steady climb going!

0 · Reply

Glizzy_Gladiator Dec. 24 at 5:49 PM

$NEO Take your time big guy we know what direction you’re going in the long run

0 · Reply

kiwitc2000 Dec. 24 at 4:15 PM

1 · Reply

ValueVester Dec. 16 at 3:01 AM

0 · Reply

DriveForShow Dec. 15 at 5:53 PM

$NEO Good news. Natera has withdrawn their appeal regarding RaDaR patent.

1 · Reply

GeeRam23 Dec. 15 at 12:23 PM

$NEO

0 · Reply

MaximillionJewell Dec. 14 at 7:11 PM

$NEO 🧐

1 · Reply

Estimize Dec. 11 at 12:00 PM

Wall St is expecting 0.04 EPS for $NEO Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/neo?chart=historical&metric_name=eps&utm_cont

0 · Reply

GeeRam23 Dec. 10 at 12:16 PM

$NEO https://ir.neogenomics.com/news-events/press-releases/detail/313/neogenomics-to-present-new-ctdna-research-at-sabcs-2025

0 · Reply

NewsAndFilings Dec. 4 at 12:54 PM

Yesterdays Recap: $RDZN Successful Closing of Its Acquisition of EliteCover $CBDW $6 Million Investment Commitment to Acquire Power Assets and Advance AI and Data Center $BLGO Subsidiary BEST Featured in Chemical Engineering Magazine $HLYK $NEO Green Plaent Microcaps Article

0 · Reply

NewsAndFilings Dec. 3 at 1:14 PM

$HLYK $NEO - HealthLynked: AI, Interoperability, and a National Policy Tailwind Converge https://richardacavalli.wixsite.com/greenplanetmicrocaps/free-app-big-moneymaker

0 · Reply

MsGrumpy Dec. 3 at 11:44 AM

$HLYK $NEO NEO founder is launching free healthcare app that is designed to be huge money maker https://richardacavalli.wixsite.com/greenplanetmicrocaps/free-app-big-moneymaker

0 · Reply

Estimize Nov. 27 at 11:00 AM

Wall St is expecting 0.04 EPS for $NEO Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/neo?chart=historical&metric_name=eps&utm_cont

0 · Reply

Glizzy_Gladiator Nov. 25 at 3:07 PM

$NEO just in it’s own lane thriving

0 · Reply

isaacwilliams33 Nov. 22 at 6:51 AM

$NUVB $NEO

0 · Reply

GeeRam23 Nov. 21 at 4:57 PM

$NEO 🔥

0 · Reply

Glizzy_Gladiator Nov. 21 at 4:28 PM

$NEO it’s a good day

0 · Reply

StockConsultant Nov. 21 at 1:31 PM

$NEO Neogenomics stock, watch for a narrow range breakout at https://stockconsultant.com/?NEO

1 · Reply

doodoodeity Nov. 20 at 8:07 PM

Not feeling particularly good about much, but took little nibbles on $NEO and $RCUS

0 · Reply

GeeRam23 Nov. 20 at 3:19 PM

$NEO

0 · Reply

Market Cap	1.64B
Revenue (ttm)	660.57M
Net Income (ttm)	-78.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.92%
Debt to Equity Ratio	0.00

Volume	1,197,400
Avg Vol	2,155,462
Day's Range	N/A - N/A
Shares Out	129.39M
Stochastic %K	87%
Beta	1.58
Analysts	Sell
Price Target	$13.94